Liposarcoma

• FDA approval · 2014-08-01
  FDA Approved: HALAVEN — Supplemental Application (BSP Pharmaceuticals SpA)

  The FDA approved a supplemental application for HALAVEN (eribulin mesylate) submitted by BSP Pharmaceuticals SpA.

• CLINICAL_TRIALS trial_result · 2012-08-28
  Clinical Trial Update: Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma [Phase 2]

  Phase II trial results for sunitinib malate in metastatic or surgically unresectable soft tissue sarcoma were posted, evaluating activity ac…

• FDA approval · 2012-02-17
  FDA Approved: HALAVEN — Supplemental Application (BSP Pharmaceuticals SpA)

  FDA approved a supplemental application for HALAVEN (eribulin mesylate) submitted by BSP Pharmaceuticals SpA.